MedTrace Logo

Active Surveillance for Low-risk Prostate Cancer - Evaluation of the Efficacy of Minimally Invasive Active Surveillance

NCT03956108 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 280

Last updated 2020-09-10

No results posted yet for this study

Summary

The STHLM3-AS study will evaluate the specificity of a new proposed protocol for active surveillance using the Stockholm3 test in combination with MRI targeted biopsies for prostate cancer detection in men with diagnosed low-risk prostate cancer undergoing active surveillance in comparison to conventional follow up using PSA and systematic biopsies.

Conditions

Interventions

DIAGNOSTIC_TEST

MRI+targeted biopsies+Stockholm3-test

MRI, evaluation in accordance with PI-RADS v2, and targeted biopsies. Stockholm3-test.

DIAGNOSTIC_TEST

PSA + systematic biopsies

Systematic biopsies and PSA test

Sponsors & Collaborators

Principal Investigators

  • Anna Lantz, MD PhD · Karolinska Institutet

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
45 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-01
Primary Completion
2019-12-12
Completion
2020-03-01

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03956108 on ClinicalTrials.gov